Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial-Reference-Cited by-同舟云学术

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Published:2013-12 Issue:13 Volume:14 Page:1278-1286
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Yamada Yasuhide,Takahari Daisuke,Matsumoto Hiroshi,Baba Hideo,Nakamura Masato,Yoshida Kazuhiro,Yoshida Motoki,Iwamoto Shigeyoshi,Shimada Ken,Komatsu Yoshito,Sasaki Yasutsuna,Satoh Taroh,Takahashi Keiichi,Mishima Hideyuki,Muro Kei,Watanabe Masahiko,Sakata Yuh,Morita Satoshi,Shimada Yasuhiro,Sugihara Kenichi

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer;Goldberg;J Clin Oncol,2004

2. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

3. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study;Saltz;J Clin Oncol,2008

4. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer;Cassidy;J Clin Oncol,2008

5. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas;Shirasaka;J Clin Oncol,2009

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib;The Oncologist;2024-09-07

2. PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer;ESMO Gastrointestinal Oncology;2024-09

3. Overall survival with non-proportional hazards in first-line treatment for patients with metastatic colorectal cancer: Systematic review and network meta-analysis;Heliyon;2024-08

4. A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases;Frontiers in Pharmacology;2024-07-26

5. Chemotoxicity and Associated Risk Factors in Colorectal Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-07-20